Article and Video CATEGORIES

Cancer Journey

Search By

Clinical Trial Spotlight: Targeting Brain Mets in EGFR Lung Cancer Patients
gracevideo
Author
GRACE Videos and Articles

LCAM 2015

 

Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.

November is Lung Cancer Awareness Month. What are you grateful for?

Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.

[powerpress]

[ratingwidget post_id=0]

Check out more LCAM videos & posts here.

Next Previous link

Previous PostNext Post

Related Content

Online Community

Hi app.92,  Welcome to Grace.  I'm sorry this is late getting to you. And more sorry your mum is going through this.  It's possible this isn't a pancoast tumor even though...

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

Here's the webinar on YouTube.  It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Recent Comments

JOIN THE CONVERSATION
Hi app.92,  Welcome to Grace…
By JanineT GRACE … on
Webinar OnDemand
By JanineT GRACE … on
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on